Parkinson's disease is characterized by the accumulation of misfolded alpha-synuclein protein aggregates (Lewy bodies) in dopaminergic neurons of the substantia nigra, leading to progressive motor dysfunction and neuronal death. This hypothesis proposes that pharmacological or genetic activation of TFEB (Transcription Factor EB) can restore lysosomal biogenesis and enhance alpha-synuclein clearance specifically in Parkinson's disease-affected brain regions. TFEB dysfunction and impaired autophagy-lysosomal pathway activity are hallmarks of Parkinson's pathogenesis, where cytoplasmic sequestration of TFEB reduces lysosomal capacity. By enhancing TFEB nuclear localization through mTORC1 inhibition, trehalose treatment, or direct TFEB overexpression, we can upregulate expression of lysosomal genes including LAMP1, cathepsins, and V-ATPase subunits. This enhanced lysosomal capacity will improve clearance of aggregated alpha-synuclein oligomers and fibrils from dopaminergic neurons, preventing their spread to interconnected brain regions via prion-like transmission.
...Curated pathway from expert analysis
flowchart TD
A["mTORC1 Hyperactivation<br/>Nutrient/Growth Signals"]
B["TFEB Phosphorylation<br/>Ser211 by mTORC1"]
C["14-3-3 Sequestration<br/>Cytoplasmic Retention"]
D["Lysosomal Biogenesis<br/>Blocked"]
E["Autophagic Flux<br/>Impaired"]
F["Tau/Amyloid Aggregate<br/>Accumulation"]
G["TFEB Activation<br/>Rapamycin or MCOLN1"]
H["Nuclear TFEB<br/>CLEAR Gene Expression"]
G --> H
H -.->|"rescues"| D
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#81c784,color:#81c784No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for TFEB yet. Search RCSB →
Median TPM across 13 brain regions for TFEB from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TFEB.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6J mice undergo chronic mTORC1 inhibition via oral rapamycin (10 mg/kg/day) for 8 weeks beginning at 8 weeks of age in the A53T alpha-synuclein transgenic model, THEN striatal dopamine levels | Striatal dopamine concentration ≥0.8 μg/mg tissue protein; latency to fall on rotarod at 24 rpm ≥180 seconds; combined improvement in open field center entries | — no observation — | pending | 0.72 |
| IF human Parkinson's disease patients with CSF alpha-synuclein oligomer levels >2 standard deviations above age-matched healthy controls receive trehalose (10% w/v, oral, twice daily) for 24 weeks, TH | CSF cathepsin D activity ≥15 nmol/hr/mL; GCase activity ≥20 nmol/hr/mL; total alpha-synuclein concentration ≤150 pg/mL; unified Parkinson's disease rating scale | — no observation — | pending | 0.68 |